Quarterly ResultAug 13, 2026, 04:20 PM
Invivyd Q2 Revenue $14.3M, PEMGARDA Sales Up 21%; Clinical Trials Advance
AI Summary
Invivyd reported Q2 2026 PEMGARDA net product revenue of $14.3 million, marking a 21% increase from Q2 2025. The company's cash and cash equivalents were $160.1 million as of June 30, 2026, providing runway through key clinical trial readouts. Net loss for the quarter increased to $44.4 million, driven by higher R&D and SG&A expenses as the company advanced its VYD2311 clinical program. Invivyd announced the completion of enrollment for its DECLARATION and LIBERTY clinical trials, with top-line data for both anticipated in late Q3 2026, and received 12 months' notice of PEMGARDA's Emergency Use Authorization termination.
Key Highlights
- Q2 2026 PEMGARDA net product revenue reached $14.3 million.
- PEMGARDA net product revenue grew 21% year-over-year from $11.8 million in Q2 2025.
- Cash and cash equivalents stood at $160.1 million as of June 30, 2026.
- Net loss for Q2 2026 was $44.4 million, compared to $14.7 million in Q2 2025.
- DECLARATION pivotal clinical trial enrollment is complete, with top-line data expected late Q3 2026.
- LIBERTY study is fully dosed, with top-line data anticipated in late Q3 2026.
- Invivyd received 12 months' advanced notice of PEMGARDA EUA termination in July 2026.
- R&D expenses increased to $29.4 million in Q2 2026 from $9.6 million in Q2 2025.
Price Impact
More from IVVD